X

Course Registration


At the completion of this symposium, participants should be able to:

  1. Discuss with patients and their families the current evidence for or against the use of intravenous vitamin C (ascorbate) as an intervention in oncology treatment or sepsis in critical care settings.
  2. Evaluate the expanding scientific evidence for the proposed mechanisms of action of intravenous vitamin C (ascorbate) as an intervention in oncology and sepsis care.
  3. Define methods in administering intravenous vitamin C (ascorbate) safely in clinical care.

Recent in vitro and animal evidence from many laboratories indicates that pharmacologic but not oral ascorbate may have selective cancer killing properties, by action as a prodrug to generate hydrogen peroxide selectively in extracellular fluid (Chen et al. 2008; Levine et al. 2011).

The use of ascorbate in oncology has long been passionately debated (Levine et al. 2009; Creagan et al. 1979).  Notwithstanding the limitations of studies performed in the late 1970’s, the idea of ascorbate as a chemotherapeutic agent seems plausible, stemming from a postulated versatile role in biochemical reactions and its selectivity for abnormal cells (Chen et al. 2005; Chen et al. 2007). Our group has elucidated the disproportionate pharmacokinetic properties between oral and intravenous (pharmacological) vitamin C administration in normal human subjects (Padayatty et al. 2004). 

Intravenous administration of ascorbate achieves 70-fold higher concentration than that achieved by maximum oral consumption in humans (Padayatty et al. 2004; Chen et al. 2008; Levine et al. 2011).  This striking concentration difference seems to be dependent on tightly-regulated mechanisms that maintain serum ascorbate concentrations when ingested orally but not when infused intravenously and intravenous infusion bypassing tight control appears to be critical for its role in oncology.


Upon completion of this course the participant should be able to:
  1. Discuss with patients and their families the current evidence for or against the use of intravenous vitamin C (ascorbate) as an intervention in oncology treatment or sepsis in critical care settings.
  2. Evaluate the expanding scientific evidence for the proposed mechanisms of action of intravenous vitamin C (ascorbate) as an intervention in oncology and sepsis care.
  3. Define methods in administering intravenous vitamin C (ascorbate) safely in clinical care.

FEES

Payment is required at the time of registration. Only registrations accompanied with payment will be accepted. Please register in advance. Fees include course materials, continental breakfast, lunch, refreshments and continuing education credit.

REFUND/CANCELLATION POLICY

A full refund of registration fees, less a $15 administrative fee, will be available if requested in writing and received by August 30, 2016. No refunds will be made after that date. A $30 fee also will be charged for returned checks. (Please note that if you fail to cancel by the deadline and do not attend, you are still responsible for payment.) KU Medical Center Continuing Education reserves the right to cancel the course and return all fees in the event of insufficient registration. The liability of the University of Kansas Medical Center is limited to the registration fee. The University of Kansas Medical Center will not be responsible for any losses incurred by registrants, including but not limited to airline cancellation charges or hotel deposits.


Early Bird Registration

After July 29, 2016

Physician

$299

$350

Advance Practice Nurse / Nurse

$299

$350

Pharmacist

$299

$350

Other Health Care Professional

$299

$350

General Public or Non-Healthcare Professional

$199

$199

Resident, Fellow or Student

$199

$199

Garry R Buettner, MD
Director, ESR Facility
The University of Iowa
Iowa City, IA
Lewis C Cantley, MD
Director, Sandra & Edward Meyer Cancer Center
Weill Cornell Medical College, NY
Qi Chen, PhD
Associate Professor
KU Medical Center
Kansas City, KS
Joseph Cullen, MD
Chief of Surgical Services
University of Iowa
Iowa City, IA
Jeanne A. Drisko, MD
Director, KU Integrative Medicine; Riordan Endowed Professor of Orthomolecular Medicine
KUMC - Program in Integrative Medicine
Kansas City, MO
Alpha Fowler III, MD
Chairman, The CVU Johnson Center for Critical Care and Pulmonary Research
VCU School of Medicine
Richmond, VA
L. John Hoffer, PhD
Project Director
Lady Davis Institute for Medical Research
Montreal, QC
Mark Levine, MD
Section Chief, Molecular and Clinical Nutrition Section
Digestive Disease Branch, NIH, MD
Daniel Monti, MD
Senior Vice President and The Ellen and Ron Caplan Professor & Director of Integrative Medicine
Thomas Jefferson University
Philadelphia, PA
Ramesh Natarajan, PhD
Professor, Internal Medicine
Virginia Commonwealth University
Richmond, VA

All participants are required to sign attendance rosters at the beginning of each day. A certificate of completion will be provided to all activity participants based on completion of the program evaluation, documentation of actual attendance time, and payment in full. If you are not paid in full, a link to complete evaluation and get your certificate will be emailed to you upon receipt of payment.

Physicians: The University of Kansas Medical Center Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The KU Medical Center Office of Continuing Medical Education designates this live activity for a maximum of 11.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: 11.5 contact hours will be awarded to all individuals based on completion of the program evaluation, documentation of actual attendance time, and payment in full.

University of Kansas School of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists: Application has been made to The Kansas State Board of Pharmacy for pre-approval of 11.5 CE hours.

Notice - Physician Information Collection:  For physician attendees, the Open Payments to Physicians (Sunshine Act) may require the company supporters(s) to report to CMS the value of some items associated with this activity.  For proper reporting, we will be asking for your NPI (National Provider Index) number and a state license number.

 

To make hotel reservations please contact the Intercontinental Plaza Hotel, 401 Ward Parkway, Kansas City, MO, 866-856-971.

PRIVACY POLICY

KU Medical Center Continuing Education does not share, sell, or rent its mailing lists. You have our assurance that any information you provide will be held in confidence by KU Medical Center Continuing Education.

We occasionally use mailing lists that we have leased. If you receive unwanted communication from KU Medical Center Continuing Education, it is because your name appears on a list we have acquired from another source. In this case, please accept our apologies.

NONDISCRIMINATION POLICY

The University of Kansas Medical Center prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University's programs and activities.  The following person has been designated to handle inquiries regarding the non-discrimination polices: Natalie Holick, Director, Equal Opportunity Office, NHolick@kumc.edu, Mail Stop 2014, 4330 Shawnee Mission Parkway, Fairway, KS 66205, 913-588-8011, 711TTY

PROGRAM ACCESSIBILITY

We accommodate persons with disabilities. Please call 913-588-4488 and a KU Medical Center Continuing Education representative will be happy to discuss your needs. To ensure accommodation, please register at least two weeks before the start of the course. See the nondiscrimination policy above. The University of Kansas Medical Center is an AA/EO Title IX institution.





© The University of Kansas Medical Center
The University of Kansas Medical Center prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University's programs and activities.  The following person has been designated to handle inquiries regarding the non-discrimination polices: Natalie Holick, Director, Equal Opportunity Office, NHolick@kumc.edu, Mail Stop 2014, 4330 Shawnee Mission Parkway, Fairway, KS 66205, 913-588-8011, 711TTY